期刊文献+

Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease 被引量:2

Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease
原文传递
导出
摘要 Continuous dopaminergic stimulation(CDS)is a prominent therapeutic concept for the treatment of Parkinson's disease(PD),which proposes that continuous brain dopamine-receptor stimulation,rather than intermittent doses of oral L-dopa,prevents or manages L-dopa-induced dyskinesias(LIDs).In the normal situation,dopaminergic neurons in the substantia nigra pars compacta fire tonically to keep the dopamine receptor stimulation at a steady-state level.But when the dopaminergic pathway is impaired,the dopamine receptor stimulation becomes intermittent or pulsatile.This pulsatile stimulation causes a series of gene and protein changes in striatal neurons,leading to alterations in the firing patterns of basal ganglia neurons that result in LIDs.Studies in animal models and clinical trials of PD have shown that approaches providing CDS,currently including patches,extended-release formulations of L-dopa or dopamine agonists,continuous delivery of apomorphine and duodenal L-dopa infusion,are associated with a decreased risk of LIDs.In this review,we summarize both preclinical and clinical evidence for the five methods that may provide CDS in theory and compare the advantages and disadvantages of these methods. Continuous dopaminergic stimulation(CDS)is a prominent therapeutic concept for the treatment of Parkinson's disease(PD),which proposes that continuous brain dopamine-receptor stimulation,rather than intermittent doses of oral L-dopa,prevents or manages L-dopa-induced dyskinesias(LIDs).In the normal situation,dopaminergic neurons in the substantia nigra pars compacta fire tonically to keep the dopamine receptor stimulation at a steady-state level.But when the dopaminergic pathway is impaired,the dopamine receptor stimulation becomes intermittent or pulsatile.This pulsatile stimulation causes a series of gene and protein changes in striatal neurons,leading to alterations in the firing patterns of basal ganglia neurons that result in LIDs.Studies in animal models and clinical trials of PD have shown that approaches providing CDS,currently including patches,extended-release formulations of L-dopa or dopamine agonists,continuous delivery of apomorphine and duodenal L-dopa infusion,are associated with a decreased risk of LIDs.In this review,we summarize both preclinical and clinical evidence for the five methods that may provide CDS in theory and compare the advantages and disadvantages of these methods.
出处 《Neuroscience Bulletin》 SCIE CAS CSCD 2013年第5期661-669,共9页 神经科学通报(英文版)
基金 supported by a grant from the Science and Technology Bureau of Zhejiang Province, China (2011c14026)
关键词 continuous dopaminergic stimulation application Parkinson's disease L-dopa-induced dyskinesias continuous dopaminergic stimulation application Parkinson's disease L-dopa-induced dyskinesias
  • 相关文献

参考文献56

  • 1Dorsey ER, Constantinescu R, Thompson JP, Biglan BM, Holloway RG, Kieburtz K, et aL Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68(5): 384-386.
  • 2Olanow CW. The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med 2004, 55: 41-60.
  • 3Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cu- mulative literature. Mov Disord 2001, 16(3): 448-458.
  • 4Linazasoro G. New ideas on the origin of L-dopa-induce( dyskinesias: age, genes and neural plasticity. Trends Phar macol Sci 2005, 26(8): 391-397.
  • 5Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinsons disease: impact of motor fluctuations and dyskinesias. Pharmacoeco- nomics 2001, 19(10): 1013-1038.
  • 6Olanow CW, Obeso JA, Stocchi F. Continuous dopamine- receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006, 5(8): 677-687.
  • 7Rascol O. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release. Eur J Neu- rol 2011, 18(Suppl 1): 3-10.
  • 8Grace A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991, 41(1): 1-24.
  • 9Metman LV, Konitsiotis S, Chase TN. Pathophysiology of mo- tor response complications in Parkinson's disease: hypoth- eses on the why, where and what. Mov Disord 2000, 15(1): 3-8.
  • 10Stocchi F. The therapeutic concept of continuous dopaminer- gic stimulation (CDS) in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009, 15(3): 68-71.

同被引文献5

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部